Skip to content Skip to footer
Top 20 Biopharma Deal Terminations of 2022 Based on Total Deal Value

Top 20 Biopharma Deal Terminations of 2022 Based on Total Deal Value

Shots:Post M&A deals, companies often cannot sail through a few key aspects of the partnership, such as limited ownership, exorbitant recovery costs, and poor integration process, leading to deal terminations. The improperly executed expansion program also contributes significantly to the failed partnershipTo tackle such scenarios, companies are cautious enough to make backup plans beforehand…

Read more

Diagnostics Companies Based Top 20 2019

Top 20 Diagnostics Companies Based on 2019 Revenue

Diagnostics has emerged as one of the largest and fastest-growing segments with evolving diseases. The segment has played a vital role in diagnosing growing and ageing global population with increasing health expenditure and more prevalent lifestyle ailments including obesity- cancer- and cardiovascular diseases. Our team at PharmaShots has compiled a list of top 20 diagnostics companies based…

Read more